{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:16Z","timestamp":1788441376403,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12672-3","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:17Z","timestamp":1788438977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanotherapeutics in osteosarcoma: Advances in miRNA nanocarriers and targeted drug delivery"],"prefix":"10.1007","volume":"53","author":[{"given":"Arnab","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman Ibrahim","family":"Yakubu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"1","key":"12672_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41572-022-00416-z","volume":"8","author":"GR Beird","year":"2022","unstructured":"Beird GR, Bielack HC, Flanagan SS, Gill AM, Heymann J, Janeway D, Livingston KA, Roberts JA, Strauss RD (2022) Osteosarcoma. Nat Rev Dis Prim 8(1):82","journal-title":"Nat Rev Dis Prim"},{"issue":"11","key":"12672_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer 14(11):722\u2013735. https:\/\/doi.org\/10.1038\/nrc3838","journal-title":"Nat Rev Cancer"},{"key":"12672_CR3","unstructured":"PDQ Pediatric Treatment Editorial Board Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ\u00ae): Health Professional Versio, no. Md. 2002. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/26389179\/"},{"key":"12672_CR4","doi-asserted-by":"publisher","unstructured":"Xu Y et al (2026) Decoding osteosarcoma from heterogeneity to precision therapy. Discov Oncol 17(1). https:\/\/doi.org\/10.1007\/s12672-025-04256-7","DOI":"10.1007\/s12672-025-04256-7"},{"key":"12672_CR5","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.2147\/IJN.S471900","volume":"19","author":"C Wang","year":"2024","unstructured":"Wang C et al (2024) Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma. Int J Nanomed 19:8641\u20138660. https:\/\/doi.org\/10.2147\/IJN.S471900","journal-title":"Int J Nanomed"},{"key":"12672_CR6","doi-asserted-by":"publisher","unstructured":"Motassime AE et al (2025) Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications. Biology (Basel) 14(10). https:\/\/doi.org\/10.3390\/biology14101407","DOI":"10.3390\/biology14101407"},{"issue":"1","key":"12672_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"Bartel DP","year":"2018","unstructured":"Bartel DP (2018) Metazoan microRNAs. Cell 173(1):20\u201351. https:\/\/doi.org\/10.1016\/j.cell.2018.03.006","journal-title":"Cell"},{"issue":"3","key":"12672_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203\u2013221. https:\/\/doi.org\/10.1038\/nrd.2016.246","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"12672_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ (2004) MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522\u2013531. https:\/\/doi.org\/10.1038\/nrg1379","journal-title":"Nat Rev Genet"},{"issue":"4","key":"12672_CR10","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/jcmm.14064","volume":"23","author":"R Chen","year":"2019","unstructured":"Chen R, Wang G, Zheng Y, Hua Y, Cai Z (2019) Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies. J Cell Mol Med 23(4):2280\u20132292. https:\/\/doi.org\/10.1111\/jcmm.14064","journal-title":"J Cell Mol Med"},{"key":"12672_CR11","doi-asserted-by":"publisher","unstructured":"Mosca N et al (2024) Osteosarcoma in a ceRNET perspective. J Biomed Sci 31(1). https:\/\/doi.org\/10.1186\/s12929-024-01049-y","DOI":"10.1186\/s12929-024-01049-y"},{"key":"12672_CR12","doi-asserted-by":"publisher","unstructured":"Chen Y, Wu X, Li J, Jiang Y, Xu K, Su J (2022) Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.909408","DOI":"10.3389\/fphar.2022.909408"},{"key":"12672_CR13","doi-asserted-by":"publisher","unstructured":"Chawra HS et al (2024) MicroRNA-21\u2019s role in PTEN suppression and PI3K\/AKT activation: Implications for cancer biology. Pathol Res Pract 254. https:\/\/doi.org\/10.1016\/j.prp.2024.155091","DOI":"10.1016\/j.prp.2024.155091"},{"key":"12672_CR14","doi-asserted-by":"publisher","unstructured":"Seyhan AA (2024) Trials and Tribulations of MicroRNA Therapeutics. Int J Mol Sci 25(3). https:\/\/doi.org\/10.3390\/ijms25031469","DOI":"10.3390\/ijms25031469"},{"key":"12672_CR15","doi-asserted-by":"publisher","unstructured":"Shi P et al (2023) Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J Nanobiotechnol 21(1). https:\/\/doi.org\/10.1186\/s12951-023-01826-1","DOI":"10.1186\/s12951-023-01826-1"},{"key":"12672_CR16","doi-asserted-by":"publisher","unstructured":"Holjencin C, Jakymiw A (2022) MicroRNAs and Their Big Therapeutic Impacts: Delivery Strategies for Cancer Intervention. Cells 11(15). https:\/\/doi.org\/10.3390\/cells11152332","DOI":"10.3390\/cells11152332"},{"key":"12672_CR17","doi-asserted-by":"publisher","unstructured":"Wu Y et al (2024) Bone targeted nano-drug and nano-delivery. Bone Res 12(1). https:\/\/doi.org\/10.1038\/s41413-024-00356-2","DOI":"10.1038\/s41413-024-00356-2"},{"key":"12672_CR18","doi-asserted-by":"publisher","unstructured":"Wang B et al (2024) Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther 9(1). https:\/\/doi.org\/10.1038\/s41392-024-01889-y","DOI":"10.1038\/s41392-024-01889-y"},{"key":"12672_CR19","doi-asserted-by":"publisher","first-page":"14787","DOI":"10.2147\/IJN.S539722","volume":"20","author":"G D\u2019Anna","year":"2025","unstructured":"D\u2019Anna G, Hanurry EY, Piperno A, Scala A (2025) In vivo Testing of Nanotherapeutics for Osteosarcoma Treatment: Translational Challenges and Solutions. Int J Nanomed 20:14787\u201314822. https:\/\/doi.org\/10.2147\/IJN.S539722","journal-title":"Int J Nanomed"},{"issue":"7","key":"12672_CR20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim T, Croce CM (2023) MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med 55(7):1314\u20131321. https:\/\/doi.org\/10.1038\/s12276-023-01050-9","journal-title":"Exp Mol Med"},{"issue":"13","key":"12672_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41388-024-02942-4","volume":"43","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene 43(13):962\u2013975. https:\/\/doi.org\/10.1038\/s41388-024-02942-4","journal-title":"Oncogene"},{"key":"12672_CR22","doi-asserted-by":"publisher","unstructured":"Jiang Y et al (2022) Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun 13(1). https:\/\/doi.org\/10.1038\/s41467-022-34689-5","DOI":"10.1038\/s41467-022-34689-5"},{"key":"12672_CR23","doi-asserted-by":"publisher","unstructured":"Yang W et al (2024) Biomimetic engineered nanoparticles target drug-resistant tumor cells and heterogeneous blood vessels for combination therapy of osteosarcoma. Chem Eng J 485. https:\/\/doi.org\/10.1016\/j.cej.2024.149761","DOI":"10.1016\/j.cej.2024.149761"},{"issue":"2","key":"12672_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cell.2024.12.005","volume":"188","author":"J Espejo Valle-Inclan","year":"2025","unstructured":"Espejo Valle-Inclan J et al (2025) Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell 188(2):352\u2013370. https:\/\/doi.org\/10.1016\/j.cell.2024.12.005","journal-title":"Cell"},{"issue":"5","key":"12672_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/path.5699","volume":"254","author":"M Kovac","year":"2021","unstructured":"Kovac M et al (2021) The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies. J Pathol 254(5):556\u2013566. https:\/\/doi.org\/10.1002\/path.5699","journal-title":"J Pathol"},{"key":"12672_CR26","doi-asserted-by":"publisher","unstructured":"Wu X, Deng W, Zhao Q, Xiong J (2025) Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma. Commun Biol 8(1). https:\/\/doi.org\/10.1038\/s42003-025-08409-w","DOI":"10.1038\/s42003-025-08409-w"},{"key":"12672_CR27","doi-asserted-by":"publisher","unstructured":"Liu B et al (2025) PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. Signal Transduct Target Ther 10(1). https:\/\/doi.org\/10.1038\/s41392-025-02250-7","DOI":"10.1038\/s41392-025-02250-7"},{"key":"12672_CR28","doi-asserted-by":"publisher","unstructured":"Amiryaghoubi N et al (2022) Smart chitosan\u2013folate hybrid magnetic nanoparticles for targeted delivery of doxorubicin to osteosarcoma cells. Colloids Surf B Biointerfaces 220. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112911","DOI":"10.1016\/j.colsurfb.2022.112911"},{"issue":"6","key":"12672_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/adhm.201300465","volume":"3","author":"SW Morton","year":"2014","unstructured":"Morton SW, Shah NJ, Quadir MA, Deng ZJ, Poon Z, Hammond PT (2014) Osteotropic therapy via targeted layer-by-layer nanoparticles. Adv Healthc Mater 3(6):867\u2013875. https:\/\/doi.org\/10.1002\/adhm.201300465","journal-title":"Adv Healthc Mater"},{"key":"12672_CR30","doi-asserted-by":"publisher","unstructured":"Dong Z et al (2022) Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma. Technol Cancer Res Treat 21. https:\/\/doi.org\/10.1177\/15330338221117386","DOI":"10.1177\/15330338221117386"},{"key":"12672_CR31","doi-asserted-by":"publisher","unstructured":"Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA (2015) MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr 3. https:\/\/doi.org\/10.3389\/fped.2015.00069","DOI":"10.3389\/fped.2015.00069"},{"key":"12672_CR32","doi-asserted-by":"publisher","unstructured":"Llobat L, Gourbault O (2021) Role of micrornas in human osteosarcoma: Future perspectives. Biomedicines 9(5). https:\/\/doi.org\/10.3390\/biomedicines9050463","DOI":"10.3390\/biomedicines9050463"},{"key":"12672_CR33","doi-asserted-by":"publisher","unstructured":"Meng X, Han Z, Yeerken W, Wang Z, Ma L, Liu H (2025) Uncovering differential gene expression between mtRNA-positive and -negative osteosarcoma cells: implications beyond mitochondrial function. Front Genet 16. https:\/\/doi.org\/10.3389\/fgene.2025.1588581","DOI":"10.3389\/fgene.2025.1588581"},{"key":"12672_CR34","doi-asserted-by":"publisher","unstructured":"Xiang Y, Yang Y, Liu J, Yang X (2023) Functional role of MicroRNA\/PI3K\/AKT axis in osteosarcoma. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1219211","DOI":"10.3389\/fonc.2023.1219211"},{"key":"12672_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/OTT.S283459","volume":"14","author":"F Li","year":"2021","unstructured":"Li F et al (2021) Bone marrow mesenchymal stem cells-derived extracellular vesicles promote proliferation, invasion and migration of osteosarcoma cells via the lncrna malatl\/mir-. Onco Targets Ther 14:737\u2013749. https:\/\/doi.org\/10.2147\/OTT.S283459","journal-title":"Onco Targets Ther"},{"issue":"3","key":"12672_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.32604\/or.2023.044085","volume":"32","author":"H Sun","year":"2024","unstructured":"Sun H et al (2024) MicroRNA-329-3p inhibits the Wnt\/\u03b2-catenin pathway and proliferation of osteosarcoma cells by targeting transcription factor 7-like 1. Oncol Res 32(3):463\u2013476. https:\/\/doi.org\/10.32604\/or.2023.044085","journal-title":"Oncol Res"},{"issue":"4","key":"12672_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1134\/S0006297916040027","volume":"81","author":"NE Kushlinskii","year":"2016","unstructured":"Kushlinskii NE, Fridman MV, Braga EA (2016) Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochem 81(4):315\u2013328. https:\/\/doi.org\/10.1134\/S0006297916040027","journal-title":"Biochem"},{"issue":"2","key":"12672_CR38","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00210-025-04521-0","volume":"399","author":"D Singh","year":"2026","unstructured":"Singh D (2026) Next-generation miRNA therapeutics: from computational design to translational engineering. Naunyn Schmiedebergs Arch Pharmacol 399(2):1589\u20131608. https:\/\/doi.org\/10.1007\/s00210-025-04521-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12672_CR39","doi-asserted-by":"publisher","unstructured":"Tian H et al (2024) MicroRNA therapeutic delivery strategies: A review. J Drug Deliv Sci Technol 93. https:\/\/doi.org\/10.1016\/j.jddst.2024.105430","DOI":"10.1016\/j.jddst.2024.105430"},{"issue":"12","key":"12672_CR40","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.62347\/jvrm8589","volume":"9","author":"L Gang","year":"2017","unstructured":"Gang L, Qun L, Liu WD, Li YS, Xu YZ, Yuan DT (2017) MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J Transl Res 9(12):5388\u20135399. https:\/\/doi.org\/10.62347\/jvrm8589","journal-title":"Am J Transl Res"},{"issue":"2","key":"12672_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS et al (2017) Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 35(2):180\u2013188. https:\/\/doi.org\/10.1007\/s10637-016-0407-y","journal-title":"Invest New Drugs"},{"issue":"5","key":"12672_CR42","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3892\/or_00000994","volume":"24","author":"H Zhang","year":"2010","unstructured":"Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F (2010) microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 24(5):1363\u20131369. https:\/\/doi.org\/10.3892\/or_00000994","journal-title":"Oncol Rep"},{"issue":"6","key":"12672_CR43","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1159\/000369660","volume":"34","author":"S Li","year":"2014","unstructured":"Li S, Li F, Cheng T (2014) TGF-\u03b21 promotes osteosarcoma cell migration and invasion through the miR-143-versican pathway. Cell Physiol Biochem 34(6):2169\u20132179. https:\/\/doi.org\/10.1159\/000369660","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"12672_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.bbrc.2014.02.007","volume":"445","author":"K Shimbo","year":"2014","unstructured":"Shimbo K et al (2014) Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun 445(2):381\u2013387. https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.007","journal-title":"Biochem Biophys Res Commun"},{"key":"12672_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.omtn.2018.04.002","volume":"11","author":"E Callegari","year":"2018","unstructured":"Callegari E et al (2018) miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Mol Ther Nucleic Acids 11:485\u2013493. https:\/\/doi.org\/10.1016\/j.omtn.2018.04.002","journal-title":"Mol Ther Nucleic Acids"},{"key":"12672_CR46","unstructured":"Tian R et al (2014) miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL., Am. J. Cancer Res., vol. 4, no. 6, pp. 738\u201350, [Online]. Available: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4266708\/"},{"key":"12672_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biopha.2018.10.037","volume":"109","author":"T Zeinali","year":"2019","unstructured":"Zeinali T, Mansoori B, Mohammadi A, Baradaran B (2019) Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother 109:195\u2013207. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.037","journal-title":"Biomed Pharmacother"},{"key":"12672_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejps.2018.07.021","volume":"123","author":"M Magalh\u00e3es","year":"2018","unstructured":"Magalh\u00e3es M et al (2018) miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells. Eur J Pharm Sci 123:28\u201342. https:\/\/doi.org\/10.1016\/j.ejps.2018.07.021","journal-title":"Eur J Pharm Sci"},{"key":"12672_CR49","doi-asserted-by":"publisher","unstructured":"Li E, Zhang J, Yuan T, Ma B (2014) miR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1, Tumor Biol., vol. 35, no. 8, pp. 7645\u20137650. https:\/\/doi.org\/10.1007\/s13277-014-2031-9","DOI":"10.1007\/s13277-014-2031-9"},{"issue":"1","key":"12672_CR50","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.bbrc.2017.11.120","volume":"495","author":"X Ji","year":"2018","unstructured":"Ji X, Wang E, Tian F (2018) MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. Biochem Biophys Res Commun 495(1):1342\u20131348. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.120","journal-title":"Biochem Biophys Res Commun"},{"key":"12672_CR51","doi-asserted-by":"publisher","unstructured":"Song Q, An Q, Niu B, Lu X, Zhang N, Cao X (2019) Role of miR-221\/222 in Tumor Development and the Underlying Mechanism. J Oncol 2019. https:\/\/doi.org\/10.1155\/2019\/7252013","DOI":"10.1155\/2019\/7252013"},{"key":"12672_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/genesandcancer.6","volume":"5","author":"L Arabi","year":"2015","unstructured":"Arabi L et al (2015) Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma \u2013 Reasons and consequences. Genes Cancer 5:1\u20132. https:\/\/doi.org\/10.18632\/genesandcancer.6","journal-title":"Genes Cancer"},{"issue":"38","key":"12672_CR53","doi-asserted-by":"publisher","first-page":"25285","DOI":"10.18632\/oncotarget.23935","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang H et al (2018) The miR-17-92 cluster\/QKI2\/\u03b2-catenin axis promotes osteosarcoma progression. Oncotarget 9(38):25285\u201325293. https:\/\/doi.org\/10.18632\/oncotarget.23935","journal-title":"Oncotarget"},{"key":"12672_CR54","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","volume":"159","author":"D Witzigmann","year":"2020","unstructured":"Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R (2020) Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev 159:344\u2013363. https:\/\/doi.org\/10.1016\/j.addr.2020.06.026","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"12672_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101\u2013124. https:\/\/doi.org\/10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discov"},{"key":"12672_CR56","doi-asserted-by":"publisher","unstructured":"Blanco E, Shen H, Ferrari M (2020) Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery *. Nanomater Neoplasms 585\u2013622. https:\/\/doi.org\/10.1201\/9780429027819-9","DOI":"10.1201\/9780429027819-9"},{"key":"12672_CR57","doi-asserted-by":"publisher","unstructured":"Hocao\u011flu R, Z\u0131k\u015fahna K, Ihlamur M (2026) Selecting nanocarrier platforms for drug delivery: a criteria-based, translational review integrating CQA\/CMC and immune interactions. Heal Nanotechnol 2(1). https:\/\/doi.org\/10.1186\/s44301-026-00026-8","DOI":"10.1186\/s44301-026-00026-8"},{"issue":"10","key":"12672_CR58","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill J, Gorlick R (2021) Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 18(10):609\u2013624. https:\/\/doi.org\/10.1038\/s41571-021-00519-8","journal-title":"Nat Rev Clin Oncol"},{"key":"12672_CR59","doi-asserted-by":"publisher","first-page":"14115","DOI":"10.2147\/IJN.S560865","volume":"20","author":"J Cai","year":"2025","unstructured":"Cai J, Yang H, He Z, Wu C (2025) Intelligent Nanomedicine Systems Utilizing Diverse Nanoparticles for Osteosarcoma Therapy: A Review. Int J Nanomed 20:14115\u201314130. https:\/\/doi.org\/10.2147\/IJN.S560865","journal-title":"Int J Nanomed"},{"key":"12672_CR60","doi-asserted-by":"publisher","unstructured":"Cai P, Fan M, Zheng P (2025) Application of responsive nano-drug carriers in bone tumor chemotherapy. J Bone Oncol 52. https:\/\/doi.org\/10.1016\/j.jbo.2025.100689","DOI":"10.1016\/j.jbo.2025.100689"},{"issue":"1","key":"12672_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/21691401.2014.953633","volume":"44","author":"H Daraee","year":"2016","unstructured":"Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A (2016) Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol 44(1):381\u2013391. https:\/\/doi.org\/10.3109\/21691401.2014.953633","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1","key":"12672_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","volume":"9","author":"ML Etheridge","year":"2013","unstructured":"Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomed Nanatechnol Biol Med 9(1):1\u201314. https:\/\/doi.org\/10.1016\/j.nano.2012.05.013","journal-title":"Nanomed Nanatechnol Biol Med"},{"key":"12672_CR63","doi-asserted-by":"publisher","unstructured":"Kortam S, Lu Z, Zreiqat H (2024) Recent advances in drug delivery systems for osteosarcoma therapy and bone regeneration. Commun Mater 5(1). https:\/\/doi.org\/10.1038\/s43246-024-00612-2","DOI":"10.1038\/s43246-024-00612-2"},{"key":"12672_CR64","doi-asserted-by":"publisher","unstructured":"Han J, Huo M, Jia C, Zhang B, Zhang F, Meng Q (2026) Recent advances in biomaterials for osteosarcoma treatment. Regen Biomater 13. https:\/\/doi.org\/10.1093\/rb\/rbaf087","DOI":"10.1093\/rb\/rbaf087"},{"key":"12672_CR65","doi-asserted-by":"publisher","unstructured":"Lu B et al (2024) The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front Immunol 15. https:\/\/doi.org\/10.3389\/fimmu.2024.1332939","DOI":"10.3389\/fimmu.2024.1332939"},{"key":"12672_CR66","doi-asserted-by":"publisher","unstructured":"Wang Y et al (2023) Marine biomaterials in biomedical nano\/micro-systems. J Nanobiotechnol 21(1). https:\/\/doi.org\/10.1186\/s12951-023-02112-w","DOI":"10.1186\/s12951-023-02112-w"},{"issue":"9","key":"12672_CR67","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1039\/d5ra06010a","volume":"16","author":"A AlAqel","year":"2026","unstructured":"AlAqel A et al (2026) Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy. RSC Adv 16(9):8008\u20138019. https:\/\/doi.org\/10.1039\/d5ra06010a","journal-title":"RSC Adv"},{"key":"12672_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.smaim.2026.03.001","volume":"7","author":"J Cang","year":"2026","unstructured":"Cang J et al (2026) A dynamic hydrogel platform enables localized delivery of microRNAs and osteogenic growth peptide for the treatment of osteosarcoma. Smart Mater Med 7:116\u2013131. https:\/\/doi.org\/10.1016\/j.smaim.2026.03.001","journal-title":"Smart Mater Med"},{"key":"12672_CR69","doi-asserted-by":"publisher","unstructured":"Li X et al (2024) Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Ther 9(1). https:\/\/doi.org\/10.1038\/s41392-023-01668-1","DOI":"10.1038\/s41392-023-01668-1"},{"key":"12672_CR70","doi-asserted-by":"publisher","unstructured":"Liu H, Chen MZ, Payne T, Porter CJH, Pouton CW, Johnston APR (2024) Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA\/LNP Delivery. Adv Funct Mater 34(39). https:\/\/doi.org\/10.1002\/adfm.202404510","DOI":"10.1002\/adfm.202404510"},{"key":"12672_CR71","doi-asserted-by":"publisher","unstructured":"Haghighi E, Abolmaali SS, Dehshahri A, Mousavi Shaegh SA, Azarpira N, Tamaddon AM (2024) Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. J Nanobiotechnol 22(1). https:\/\/doi.org\/10.1186\/s12951-024-02972-w","DOI":"10.1186\/s12951-024-02972-w"},{"key":"12672_CR72","doi-asserted-by":"publisher","unstructured":"Wang R et al (2026) Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies. Int J Nanomed 21. https:\/\/doi.org\/10.2147\/IJN.S580526","DOI":"10.2147\/IJN.S580526"},{"key":"12672_CR73","doi-asserted-by":"publisher","unstructured":"Xu H, Li S, Liu YS (2022) Nanoparticles in the diagnosis and treatment of vascular aging and related diseases. Signal Transduct Target Ther 7(1). https:\/\/doi.org\/10.1038\/s41392-022-01082-z","DOI":"10.1038\/s41392-022-01082-z"},{"issue":"4","key":"12672_CR74","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1039\/d3cs00805c","volume":"53","author":"A Slezak","year":"2024","unstructured":"Slezak A et al (2024) Therapeutic synthetic and natural materials for immunoengineering. Chem Soc Rev 53(4):1789\u20131822. https:\/\/doi.org\/10.1039\/d3cs00805c","journal-title":"Chem Soc Rev"},{"key":"12672_CR75","doi-asserted-by":"publisher","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M (2023) Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discov Nano 18(1). https:\/\/doi.org\/10.1186\/s11671-023-03943-0","DOI":"10.1186\/s11671-023-03943-0"},{"key":"12672_CR76","doi-asserted-by":"publisher","unstructured":"Xu B, Li S, Shi R, Liu H (2023) Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct Target Ther 8(1). https:\/\/doi.org\/10.1038\/s41392-023-01654-7","DOI":"10.1038\/s41392-023-01654-7"},{"key":"12672_CR77","doi-asserted-by":"publisher","unstructured":"Dutta Gupta Y, Mackeyev Y, Krishnan S, Bhandary S (2024) Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nanotechnol 15(1). https:\/\/doi.org\/10.1186\/s12645-024-00250-w","DOI":"10.1186\/s12645-024-00250-w"},{"issue":"3","key":"12672_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.34172\/apb.2024.046","volume":"14","author":"JO Erebor","year":"2024","unstructured":"Erebor JO, Agboluaje EO, Perkins AM, Krishnakumar M, Ngwuluka N (2024) Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy. Adv Pharm Bull 14(3):558\u2013573. https:\/\/doi.org\/10.34172\/apb.2024.046","journal-title":"Adv Pharm Bull"},{"key":"12672_CR79","doi-asserted-by":"publisher","unstructured":"Sarkar A, Nandi A, Bhattacharya D (2026) Nanoparticles for Targeted Cancer Therapy: Mechanisms, Benefits, and Challenges. Int J Innov Sci Res Technol 3343. https:\/\/doi.org\/10.38124\/ijisrt\/26may2014","DOI":"10.38124\/ijisrt\/26may2014"},{"key":"12672_CR80","doi-asserted-by":"publisher","unstructured":"Sanadgol N et al (2025) Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnol 23(1). https:\/\/doi.org\/10.1186\/s12951-025-03528-2","DOI":"10.1186\/s12951-025-03528-2"},{"issue":"4","key":"12672_CR81","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s12276-024-01209-y","volume":"56","author":"YJ Lee","year":"2024","unstructured":"Lee YJ, Shin KJ, Chae YC (2024) Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer. Exp Mol Med 56(4):877\u2013889. https:\/\/doi.org\/10.1038\/s12276-024-01209-y","journal-title":"Exp Mol Med"},{"key":"12672_CR82","doi-asserted-by":"publisher","unstructured":"Iqbal Z et al (2024) Exosome for mRNA delivery: strategies and therapeutic applications. J Nanobiotechnol 22(1). https:\/\/doi.org\/10.1186\/s12951-024-02634-x","DOI":"10.1186\/s12951-024-02634-x"},{"key":"12672_CR83","doi-asserted-by":"publisher","unstructured":"Kapadia CH, Luo B, Dang MN, Irvin-Choy N, Valcourt DM, Day ES (2020) Polymer nanocarriers for MicroRNA delivery. J Appl Polym Sci 137(25). https:\/\/doi.org\/10.1002\/app.48651","DOI":"10.1002\/app.48651"},{"key":"12672_CR84","doi-asserted-by":"publisher","unstructured":"Kara G, Ozpolat B (2024) SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer. Biomed Microdevices 26(1). https:\/\/doi.org\/10.1007\/s10544-024-00698-y","DOI":"10.1007\/s10544-024-00698-y"},{"issue":"48","key":"12672_CR85","doi-asserted-by":"publisher","first-page":"12540","DOI":"10.1039\/d4tb01541j","volume":"12","author":"E Crisafulli","year":"2024","unstructured":"Crisafulli E, Scalzone A, Tonda-Turo C, Gir\u00f3n-Hern\u00e1ndez J, Gentile P (2024) Multimodal layer-by-layer nanoparticles: a breakthrough in gene and drug delivery for osteosarcoma. J Mater Chem B 12(48):12540\u201312552. https:\/\/doi.org\/10.1039\/d4tb01541j","journal-title":"J Mater Chem B"},{"key":"12672_CR86","doi-asserted-by":"publisher","unstructured":"Tang J, He J, Feng C, Tu C (2022) Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.902049","DOI":"10.3389\/fphar.2022.902049"},{"key":"12672_CR87","doi-asserted-by":"publisher","unstructured":"Liu JJJ, Liu D, To SKY, Wong AST (2025) Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer 24(1). https:\/\/doi.org\/10.1186\/s12943-025-02372-0","DOI":"10.1186\/s12943-025-02372-0"},{"key":"12672_CR88","doi-asserted-by":"publisher","unstructured":"Fu H, Wu Y, Chen J, Hu X, Wang X, Xu G (2023) Exosomes and osteosarcoma drug resistance. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1133726","DOI":"10.3389\/fonc.2023.1133726"},{"key":"12672_CR89","doi-asserted-by":"publisher","unstructured":"Zhang H, Luo P, Huang X (2023) Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1269224","DOI":"10.3389\/fphar.2023.1269224"},{"key":"12672_CR90","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.2147\/IJN.S548088","volume":"20","author":"R Zeinali","year":"2025","unstructured":"Zeinali R, Zaeifi D, Zolfaghari-Moghaddam SY, Paul MK, Biazar E (2025) Current Advances in Nanocarriers for Cancer Therapy. Int J Nanomed 20:12217\u201312262. https:\/\/doi.org\/10.2147\/IJN.S548088","journal-title":"Int J Nanomed"},{"key":"12672_CR91","doi-asserted-by":"publisher","unstructured":"Shakori Poshteh S, Alipour S, Varamini P (2024) Harnessing curcumin and nanotechnology for enhanced treatment of breast cancer bone metastasis. Discov Nano 19(1). https:\/\/doi.org\/10.1186\/s11671-024-04126-1","DOI":"10.1186\/s11671-024-04126-1"},{"issue":"11","key":"12672_CR92","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS et al (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 122(11):1630\u20131637. https:\/\/doi.org\/10.1038\/s41416-020-0802-1","journal-title":"Br J Cancer"},{"key":"12672_CR93","unstructured":"Safety A, Agency E (2018) A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma and lung cancer, [Online]. Available: https:\/\/www.asbestossafety.gov.au\/research-publications\/phase-i-study-targomirs-patients-refractory-malignant-pleural-mesothelioma"},{"issue":"3","key":"12672_CR94","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"AG Seto","year":"2018","unstructured":"Seto AG et al (2018) Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol 183(3):428\u2013444. https:\/\/doi.org\/10.1111\/bjh.15547","journal-title":"Br J Haematol"},{"issue":"5","key":"12672_CR95","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","volume":"139","author":"CL Gallant-Behm","year":"2019","unstructured":"Gallant-Behm CL et al (2019) A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol 139(5):1073\u20131081. https:\/\/doi.org\/10.1016\/j.jid.2018.11.007","journal-title":"J Invest Dermatol"},{"key":"12672_CR96","doi-asserted-by":"publisher","unstructured":"Zhang Y et al (2025) Nanotechnology revolutionizing osteosarcoma treatment: Advances in targeted kinase inhibitors. Nanotechnol Rev 14(1). https:\/\/doi.org\/10.1515\/ntrev-2025-0147","DOI":"10.1515\/ntrev-2025-0147"},{"key":"12672_CR97","doi-asserted-by":"publisher","unstructured":"Giacchi L, Pucci E, Rucci N (2026) From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma. Cancers (Basel) 18(4). https:\/\/doi.org\/10.3390\/cancers18040561","DOI":"10.3390\/cancers18040561"},{"key":"12672_CR98","doi-asserted-by":"publisher","first-page":"1813288","DOI":"10.3389\/fbioe.2026.1813288","volume":"14","author":"Q Li","year":"2026","unstructured":"Li Q, Duan S, Zhang M (2026) AI-enabled photoresponsive nanoplatforms for coordinated osteosarcoma therapy and bone regeneration. Front Bioeng Biotechnol 14:1813288. https:\/\/doi.org\/10.3389\/fbioe.2026.1813288","journal-title":"Front Bioeng Biotechnol"},{"key":"12672_CR99","doi-asserted-by":"publisher","unstructured":"Guan C, Mendes BB, Conniot J, Dias AL, Hammad L, Thambi T, Langer R, Rodrigues T, Conde J, de la Fuente-Nunez C (2025) Accelerating discoveries in cancer nanomedicine using AI. Cell Biomaterials Article 100279. https:\/\/doi.org\/10.1016\/j.celbio.2025.100279","DOI":"10.1016\/j.celbio.2025.100279"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12672-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:19Z","timestamp":1788438979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12672-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12672"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12672-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","label":"Disclosure statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1514"}}